Hopes remain for Unity Biotechnology Inc.’s UBX-1325 in diabetic macular edema (DME) following a phase II miss in wet age-related macular degeneration (AMD), where data from part A of the study called Envision fell short of the non-inferiority threshold when compared to Eylea (aflibercept, Regeneron Pharmaceuticals Inc.) through 24 weeks.